William Burgan

William Burgan

UNVERIFIED PROFILE

Are you William Burgan?   Register this Author

Register author
William Burgan

William Burgan

Publications by authors named "William Burgan"

Are you William Burgan?   Register this Author

23Publications

479Reads

43Profile Views

Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers.

Cancer Res 2020 Jan 7. Epub 2020 Jan 7.

National Cancer Institute-RAS Initiative, Frederick National Laboratory for Cancer Research, Frederick, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-19-1363DOI Listing
January 2020

Differential Effector Engagement by Oncogenic KRAS.

Cell Rep 2018 02;22(7):1889-1902

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, 1450 3rd Street, San Francisco, CA 94158, USA; Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., P.O. Box B, Frederick, MD 21702, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2018.01.051DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343826PMC
February 2018

A Gene Expression Signature Associated with Overall Survival in Patients with Hepatocellular Carcinoma Suggests a New Treatment Strategy.

Mol Pharmacol 2016 Feb 14;89(2):263-72. Epub 2015 Dec 14.

Laboratory of Cell Biology (J-P.G., J.P.M., C-P.W., A.M.C., S.V.A., M.M.G.) and Laboratory of Experimental Carcinogenesis (J.B.A., S.S.T.), Center for Cancer Research, National Cancer Institute, and Bioinformatics and Computational Biosciences Branch, Office of Cyber Infrastructure and Computational Biology, Office of Science Management and Operations, National Institute of Allergy and Infectious Diseases (S.V.), National Institutes of Health, Bethesda, Maryland; and the Viral Technologies Group and Molecular Detection Group, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research, National Institutes of Health, Frederick, Marylanld (R.K.B., K.P., W.E.B.)

View Article

Download full-text PDF

Source
http://molpharm.aspetjournals.org/content/early/2015/12/14/m
Web Search
http://molpharm.aspetjournals.org/content/89/2/263.full.pdf
Web Search
http://molpharm.aspetjournals.org/cgi/doi/10.1124/mol.115.10
Publisher Site
http://dx.doi.org/10.1124/mol.115.101360DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727122PMC
February 2016

Molecular profiling indicates orthotopic xenograft of glioma cell lines simulate a subclass of human glioblastoma.

J Cell Mol Med 2012 Mar;16(3):545-54

Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1582-4934.2011.01345.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164941PMC
March 2012

In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide.

Clin Cancer Res 2008 Feb;14(3):931-8

Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-1856DOI Listing
February 2008

Inhibition of hsp90 compromises the DNA damage response to radiation.

Cancer Res 2006 Sep;66(18):9211-20

Molecular Radiation Therapeutics and Radiation Oncology Branches, National Cancer Institute, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-06-2181DOI Listing
September 2006

ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition.

Cancer Res 2005 Aug;65(15):6967-75

Molecular Radiation Therapeutics and Radiation Oncology Branches, National Cancer Institute, Bethesda, Maryland 20892-7440, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-05-1304DOI Listing
August 2005

Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine.

Clin Cancer Res 2005 Jun;11(12):4571-9

Molecular Radiation Therapeutics Branch, National Cancer Institute, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-0050DOI Listing
June 2005

Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid.

Int J Cancer 2005 Apr;114(3):380-6

Radiation Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.20774DOI Listing
April 2005

Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin.

Clin Cancer Res 2004 Dec;10(23):8077-84

Molecular Radiation Therapeutics Branch, Radiation Oncology Branch, Developmental Therapeutics Program, National Cancer Institute, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-04-1212DOI Listing
December 2004

Transcriptional signature of flavopiridol-induced tumor cell death.

Mol Cancer Ther 2004 Jul;3(7):861-72

Molecular Radiation Therapeutics Branch, National Cancer Institute, Bethesda, Maryland 20892-1002, USA.

View Article

Download full-text PDF

Source
July 2004

Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of gammaH2AX foci.

Mol Cancer Ther 2004 Apr;3(4):409-16

Radiation Oncology Branch, National Cancer Institute, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
April 2004

Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275.

Cancer Res 2004 Jan;64(1):316-21

Radiation Oncology Branch and Molecular Radiation Therapeutics Branch, Radiation Oncology Sciences Program, Medicine Branch, National Cancer Institute, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.can-03-2630DOI Listing
January 2004

Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity.

Cancer Res 2003 Nov;63(21):7377-83

Molecular Radiation Therapeutics Branch, Radiation Oncology Science Program, National Cancer Institute, EPN/6015A, 6130 Executive Boulevard, Bethesda, MD 20892-7440, USA.

View Article

Download full-text PDF

Source
November 2003

Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization.

Clin Cancer Res 2003 Sep;9(10 Pt 1):3749-55

Molecular Radiation Therapeutics Branch, Radiation Oncology Science Program, National Cancer Institute, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
September 2003